和誉-B(02256.HK) 公布，其附属和誉医药将在2025年美国临床肿瘤学会(ASCO)年会上，以口头报告形式展示其自主研发的小分子CSF-1R抑制剂匹米替尼治疗腱鞘巨细胞瘤(TGCT)的疗效、安全性和临床结果评估的3期研究结果。2025年ASCO年会将于5月30日至6月3日在美国芝加哥举行。(jl/da)(港股报价延迟最少十五分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.